DK1261622T3 - Oprenset rekombinant hLH med en specifik bioaktivitet og fremgangsmåde til oprensning deraf - Google Patents

Oprenset rekombinant hLH med en specifik bioaktivitet og fremgangsmåde til oprensning deraf

Info

Publication number
DK1261622T3
DK1261622T3 DK01907476T DK01907476T DK1261622T3 DK 1261622 T3 DK1261622 T3 DK 1261622T3 DK 01907476 T DK01907476 T DK 01907476T DK 01907476 T DK01907476 T DK 01907476T DK 1261622 T3 DK1261622 T3 DK 1261622T3
Authority
DK
Denmark
Prior art keywords
purification
specific bioactivity
purified recombinant
ion
reverse phase
Prior art date
Application number
DK01907476T
Other languages
Danish (da)
English (en)
Inventor
Gianfranco Paradisi
Mara Rossi
Laura Scaglia
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of DK1261622T3 publication Critical patent/DK1261622T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Semiconductor Lasers (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DK01907476T 2000-02-22 2001-01-22 Oprenset rekombinant hLH med en specifik bioaktivitet og fremgangsmåde til oprensning deraf DK1261622T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00103692 2000-02-22
PCT/EP2001/000666 WO2001062774A2 (en) 2000-02-22 2001-01-22 Purified lh

Publications (1)

Publication Number Publication Date
DK1261622T3 true DK1261622T3 (da) 2007-05-29

Family

ID=8167926

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01907476T DK1261622T3 (da) 2000-02-22 2001-01-22 Oprenset rekombinant hLH med en specifik bioaktivitet og fremgangsmåde til oprensning deraf

Country Status (30)

Country Link
US (2) US7053054B2 (enExample)
EP (2) EP1777231A3 (enExample)
JP (1) JP4959898B2 (enExample)
KR (1) KR100808149B1 (enExample)
CN (1) CN100480258C (enExample)
AT (1) ATE356138T1 (enExample)
AU (1) AU780377B2 (enExample)
BG (1) BG65761B1 (enExample)
BR (2) BR122012018280B8 (enExample)
CA (1) CA2399100C (enExample)
CY (1) CY1108056T1 (enExample)
CZ (1) CZ303274B6 (enExample)
DE (1) DE60127100T2 (enExample)
DK (1) DK1261622T3 (enExample)
EA (1) EA004385B1 (enExample)
EE (1) EE04932B1 (enExample)
ES (1) ES2278722T3 (enExample)
HR (1) HRP20020651B1 (enExample)
HU (1) HU227007B1 (enExample)
IL (2) IL151309A0 (enExample)
MX (1) MXPA02007867A (enExample)
NO (1) NO328693B1 (enExample)
PL (1) PL207728B1 (enExample)
PT (1) PT1261622E (enExample)
RS (1) RS50416B (enExample)
SI (1) SI1261622T1 (enExample)
SK (1) SK287041B6 (enExample)
UA (2) UA92145C2 (enExample)
WO (1) WO2001062774A2 (enExample)
ZA (1) ZA200206108B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL207728B1 (pl) * 2000-02-22 2011-01-31 Serono Lab Sposób oczyszczania LH z próbki, zastosowanie rekombinowanego hLH oraz kompozycja farmaceutyczna
DE10235168A1 (de) * 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
NZ542549A (en) * 2003-03-04 2008-11-28 Aspenbio Pharma Inc Methods and kits for maintaining pregnancy, treating follicular cysts, and synchronizing ovulation using single-chain luteinizing hormone
CN1283792C (zh) * 2003-11-14 2006-11-08 余伟明 生物大分子组分相分离法
AU2004309040B2 (en) * 2003-12-22 2010-12-16 Ares Trading S.A. Method for purifying FSH
US20060148699A1 (en) * 2004-10-04 2006-07-06 Avi Tovi Counterion exchange process for peptides
BRPI0517973B8 (pt) * 2004-11-09 2021-05-25 Ares Trading Sa métodos para purificar o fsh recombinante
SI1917276T1 (en) 2005-08-26 2018-05-31 Ares Trading S.A. PROCEDURE FOR PREPARATION OF GLYCOSYLATED INTERFERONE BETA
AU2006323925B2 (en) * 2005-12-09 2012-08-02 Ares Trading S.A. Method for purifying FSH or a FSH mutant
US20100249381A1 (en) * 2007-10-22 2010-09-30 David Delvaille Method for Purifying FC-Fusion Proteins
AU2008314689A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying an Fc-containing protein
CN101928342B (zh) * 2009-06-18 2013-05-08 上海天伟生物制药有限公司 一种高纯度绝经期促性腺素及其制备方法和用途
CN106999546A (zh) * 2014-05-01 2017-08-01 弗吉尼亚技术知识资产公司 角蛋白纳米材料及其制备方法
CN104569441B (zh) * 2015-01-19 2016-02-03 成都大熊猫繁育研究基地 大熊猫尿液促黄体素的酶联检测方法及其应用
CA3140267A1 (en) 2019-05-16 2020-11-19 Ceva Sante Animale Compositions and methods for increasing reproduction performance in non-human mammals using recombinant luteinizing hormone

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002757A1 (en) * 1988-09-02 1990-03-22 Integrated Genetics, Inc. Heteropolymeric protein
EP0461200B1 (en) 1989-02-21 1997-01-22 Washington University Modified forms of reproductive hormones
US5087615A (en) * 1989-03-17 1992-02-11 Applied Research Systems Ars Holding N.V. Novel method of ovulation induction in humans
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
IT1287138B1 (it) * 1996-11-07 1998-08-04 Ibsa Inst Biochimique Sa Procedimento per la separazione e purificazione di fsh e lh
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
CN1302010C (zh) * 1997-06-25 2007-02-28 应用研究系统Ars股份公司 二硫键交联的糖蛋白激素类似物及其制备和应用
PL207728B1 (pl) * 2000-02-22 2011-01-31 Serono Lab Sposób oczyszczania LH z próbki, zastosowanie rekombinowanego hLH oraz kompozycja farmaceutyczna

Also Published As

Publication number Publication date
US20030186893A1 (en) 2003-10-02
CN100480258C (zh) 2009-04-22
AU3543601A (en) 2001-09-03
WO2001062774A3 (en) 2002-03-14
RS50416B (sr) 2009-12-31
CA2399100A1 (en) 2001-08-30
EE04932B1 (et) 2007-12-17
PL362891A1 (en) 2004-11-02
PL207728B1 (pl) 2011-01-31
JP2003532636A (ja) 2003-11-05
MXPA02007867A (es) 2003-02-10
BG107001A (bg) 2003-04-30
US7053054B2 (en) 2006-05-30
HRP20020651B1 (en) 2011-01-31
BRPI0108553B8 (pt) 2021-05-25
ES2278722T3 (es) 2007-08-16
EP1777231A3 (en) 2007-11-07
ZA200206108B (en) 2003-07-31
HU227007B1 (en) 2010-04-28
WO2001062774A2 (en) 2001-08-30
CY1108056T1 (el) 2013-09-04
NO20023963L (no) 2002-08-20
EP1261622B1 (en) 2007-03-07
IL151309A0 (en) 2003-04-10
AU780377B2 (en) 2005-03-17
NO328693B1 (no) 2010-04-26
IL151309A (en) 2010-11-30
CA2399100C (en) 2011-11-08
PT1261622E (pt) 2007-04-30
SI1261622T1 (sl) 2007-06-30
BRPI0108553B1 (pt) 2016-06-14
US20060079460A1 (en) 2006-04-13
EA004385B1 (ru) 2004-04-29
HUP0301814A3 (en) 2004-10-28
DE60127100T2 (de) 2007-06-28
HUP0301814A2 (hu) 2003-08-28
UA78676C2 (en) 2007-04-25
ATE356138T1 (de) 2007-03-15
EE200200464A (et) 2003-12-15
CZ20022856A3 (cs) 2003-01-15
SK287041B6 (sk) 2009-10-07
BR0108553A (pt) 2003-12-23
EP1777231A2 (en) 2007-04-25
DE60127100D1 (de) 2007-04-19
NO20023963D0 (no) 2002-08-20
HRP20020651A2 (en) 2004-12-31
BR122012018280B8 (pt) 2021-05-25
CZ303274B6 (cs) 2012-07-11
SK12052002A3 (sk) 2002-12-03
BR122012018280B1 (pt) 2018-01-09
EA200200893A1 (ru) 2003-02-27
EP1261622A2 (en) 2002-12-04
KR100808149B1 (ko) 2008-02-29
KR20030001358A (ko) 2003-01-06
CN1404486A (zh) 2003-03-19
JP4959898B2 (ja) 2012-06-27
BG65761B1 (bg) 2009-10-30
HK1052014A1 (zh) 2003-08-29
YU60302A (sh) 2005-09-19
UA92145C2 (en) 2010-10-11

Similar Documents

Publication Publication Date Title
DK1261622T3 (da) Oprenset rekombinant hLH med en specifik bioaktivitet og fremgangsmåde til oprensning deraf
CY1108460T1 (el) Μεθοδος για τον καθαρισμο ανασυνδυασμενης hcg (ανθρωπινης χοριονικης γοναδοτροπινης) που εχει ειδικη βιοδραστικοτητα
DK0906122T3 (da) Aktiverede linkers og fremgangsmåde til at fremstille og oprense disse
BRPI0010677B8 (pt) processo de purificação de gonadotropinas urinárias humanas a partir de gonadotropinas brutas.
EP0301314A3 (en) A method for the purification of interferon
Hooper et al. Histone III: II. ISOLATION AND SEQUENCES OF CHYMOTRYPTIC PEPTIDES FROM CALF THYMUS HISTONE III
Sano et al. Side reactions of hydrogen fluoride on peptides containing glutamic acid in or near the C-terminus in solid phase synthesis
ATE446967T1 (de) Chromatographische auftrennung therapeutischer polypeptide
IT1245230B (it) Procedimento di preparazione della timopentina
KR950018050A (ko) 사람 글리센틴의 제조방법
Liao et al. Analysis of V8 Protease Peptide Mapping of Recombinant Human Insulin by Capillary Zone Electrophoresis